Skip to content

Replimune Group REPL Lease Liability Payments - Due Year Two

Lease Liability Payments - Due Year Two at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$1.49M-49.3%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's lease liability payments - due year two.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's lease liability payments - due year two?
Replimune Group (REPL) reported lease liability payments - due year two of $2.97M in Q4 2025.
How has Replimune Group's lease liability payments - due year two changed year-over-year?
Replimune Group's lease liability payments - due year two increased by 3.0% year-over-year, from $2.88M to $2.97M.
What does lease liability payments - due year two mean?
This metric identifies the total cash payments required for operating and finance leases in the second year following the current balance sheet date. It helps investors forecast long-term fixed cost commitments and cash flow requirements. It is essential for modeling the company's future solvency and operational leverage.